 All patients that discontinue treatment for any other cause different to disease progression will be evaluated in the follow-up period every two months for 1 additional year, for disease status, survival and safety including second primary malignancies. All patients that have progressed at the end of treatment will be followed for survival and safety only including second primary malignancy, being phone contact acceptable. 